Aula sobre Trasplantes de Órganos Sólidos - Roche Trasplantes

Clínica y Diagnóstico - Ponencias7. Tullius SG, Hancock W, Heemann U, Azuma H, Tilney N. Reversibilityof chronic renal allograft rejection. Transplantation1994; 58: 93-99.8. González Molina M, Serón D, García del Moral R, et al. forthe Spanish Mycophenolate Mofetil and Chronic Graft NephropathyStudy Group. Treatment of chronic allograft nephropathywith mycophenolate mofetil after kidney transplantation.A Spanish multicenter study. Transplant Proc (in press).9. Isoniemi HM, Krogerus L, Von Willebrand E, et al. Histopathologicalfindings in well functioning long term renal allografts.Kidney Int 1992; 41:155-160.10. Dimény E, Wahlberg J, Larsson E, Fellström B. Can histopathologicalfindings in early renal allograft biopsies identifypatients at risk for chronic vascular rejection? Clin Transplant1995; 9: 79-84.11. Serón D, Moreso F, Bover J, et al. Early protocol renal allograftbiopsies and graft outcome. Kidney Int 1997; 51: 310-317.12. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2year protocol biopsies from a U.S. multicenter kidney transplanttrial comparing tacrolimus versus Cyclosporine. Transplantation1998; 66: 1736-1740.13. Rush ND, Jeffery JR, Gough J. Sequential protocol biopsies inrenal transplant patients. Transplantation 1995; 50: 511-514.14. Legendre C, Thervet E, Skhiri H, et al. Histologic features ofchronic allograft nephropathy revealed by protocol biopsiesin kidney transplant recipients. Transplantation 1998; 65:1506-1509.15. Serón D, Moreso F, Ramón JM, et al. Protocol renal allograftbiopsies and the design of clinical trials aimed to prevent ortreat chronic allograft nephropathy. Transplantation 2000;69:1849-1855.16. Uretsky BF, Murali S, Reddy PS, et al. Development of coronaryartery disease in cardiac transplant patients receivingimmunopsuppressive therapy cyclosporine and prednisone.Circulation 1987; 76: 827-834.17. Kobashigawa JA, Katznelson S, Laks H, M et al. Effect ofpravastatin on outcomes after cardiac transplantation. N EnglJ Med 1995; 333: 621-627.18. Wang H, Kjellstrand CM, Cockfield SM. Solez K. On the influenceof sample size on the prognostic accuracy and reproducibilityof renal transplant biopsy. Nephrol Dial Transplant1998;13: 165-172.19. Bosmans JL, Woestenburg A, Ysebaert DK, Chapelle T, HelbertMJ, Corthouts R et al. Fibrous intimal thickening at implantationas a risk factor for outcome of cadaveric renal allografts.Transplantation 2000; 69: 2388-2394.20. Marcussen M, Olsen TS, Benediktsson H, Racusen L, SolezK. Reproducibility of the Banff classification of renal allograftpathology. Transplantation 1995; 60: 1083-1089.21. Furness PN, Kirkpatrick U, Taub N, Davies DR, Solez K. AUK-wide trial of the Banff classification of renal transplantpathology in routine diagnostic practice. Nephrol Dial Transplant1997; 12: 995-1000.22. Furness PN, Taub N, Assmann K, et al. International variationin the interpretation of renal transplant biopsies. KidneyInt (in press)23. Moreso F, Lopez M, Vallejos A, et al. Serial protocol biopsiesto quantify the progression of chronic transplant nephropathyin stable renal allografts. Am J Transplantation 2001; 1: 82-88.24. Nicholson ML, McCulloch TA, Harper SJ, et al. Early measurementof interstitial fibrosis predicts long term renal functionand graft survival in renal transplantation. British J Surg1996; 83: 1082-1085.25. Nicholson ML, Bailey E, Williams S, Harris PG, FurnessPN. Computarized histomorphometric assessmentof protocol renal transplant biopsy specimens for surrogatemarkers of chronic rejection. Transplantation1999; 68: 236-241.26. Faye Sweat HT, Holde Puchtler MD, Sanford IR, Augusta GA:Sirius Red F3BA as a stain for connective tissue. Archives Pathol1981; 78: 69-72.27. Moreso F, Serón D, Vitrià J, et al. Quantification of interstitialchronic renal damage by means of texture analysis. KidneyInt 1994; 46: 1721-1727.28. Masseroli M, O’Valle F, Andújar M, et al. Design and validationof a new image analysis method for authomatic quantificationof interstitial fibrosis and glomerular morphometry.Lab Invest 1998; 78: 511-522.29. Nickerson P, Jeffry J, Cough J, et al. Identification of clinicaland histological risk factors for diminished renal function 2years posttransplant. J Am Soc Nephrol 1998; 9: 482-487.30. Hunsicker LG, Bennet LE. Design of trials of methods to reducelate renal allograft loss: the price of success. Kidney Int1995; 48 (Suppl 52) : 120-123.123